Nexentis Technologies NXTS
NASDAQ NXTS
$1.44 +0.01 (+0.70%)
At close: Oct 2, 2026 · 4:00 PM EDT

Nexentis Technologies (NXTS) Gains from Sales and Divestitures (2023 - 2024)

Updated

Nexentis Technologies' Gains from Sales and Divestitures was $3,000 in FY2025.

Analysis

Nexentis Technologies (NXTS) Gains from Sales and Divestitures (2023 - 2024) Analysis & Trends

From FY2018 onward, Nexentis Technologies has reported Gains from Sales and Divestitures for 4 years.

  • The FY2025 figure marks the lowest annual Gains from Sales and Divestitures since FY2020.
  • Per Business Quant data, Gains from Sales and Divestitures in earlier years was $12,000 in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Nexentis Technologies 1.18 Mn -21.59 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 -1.00
Dec 31, 2023 -294.00
API Access

Nexentis Technologies Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=NXTS&period=max&api_key=YOUR_API_KEY